ORPHA:466670
Cyanide poisoning
Publications
3,308
Trials
1
Interventional, condition-specific
Researchers
974
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare intoxication characterized by onset of toxic manifestations within seconds to hours - depending on the route, duration, dosage, and source of exposure - after inhalation of volatile cyanides (especially from fire smoke), ingestion of cyanide (including use of certain medications) or contact with the skin or mucous membranes. In severe cases following inhalation, signs of hyperventilation appear within seconds or minutes and are followed by loss of consciousness with convulsions and ultimately cardiovascular collapse and/or respiratory arrest. Other clinical signs include dizziness, weakness, palpitations, and anxiety, followed by dyspnea, pulmonary edema, confusion, , and paralysis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,308 matched papers (1,439 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
3,308
3,308 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
3,308 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,439 in the last 10 years · low confidence
Phrase hits: 3,308 · MeSH hits: 0
Who's working on it?
974
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Bebarta VS6 papers · 2026
Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado 80045, USA.
Papers in Europe PMC - 02Enoki Y4 papers · 2023
Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Papers in Europe PMC - 03Lee S4 papers · 2025
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Papers in Europe PMC - 04Liu Y4 papers · 2026
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, PR China.
Papers in Europe PMC - 05Matsumoto K4 papers · 2023
Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Papers in Europe PMC - 06Nath AK4 papers · 2026
Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA.
Papers in Europe PMC - 07Suzuki Y4 papers · 2023
Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Papers in Europe PMC - 08Taguchi K4 papers · 2023
Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. Electronic address: taguchi-kz@pha.keio.ac.jp.
Papers in Europe PMC - 09Wang S4 papers · 2025
Department of Plastic and Reconstructive Surgery, University of Southern California, Los Angeles, CA, USA.
Papers in Europe PMC - 10Zhang Y4 papers · 2026
Department of Emergency Medicine, Medical Key Laboratory of Poisoning Diseases of Henan Province, The First Affiliated Hospital of Zhengzhou University, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 121 trials are registered for poisoning, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
low confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: poisoning
121
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06811675·RECRUITING·The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon Monoxide Poisoning
Conditions: Carbon Monoxide Poisoning · Delayed Neurocognitive Sequelae·Matched via name phrase
- NCT07103356·RECRUITING·Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire
Conditions: Arsenic Poisoning · Environmental Exposure · Water-Related Diseases·Matched via name phrase
- NCT07234383·NOT YET RECRUITING·Accelerated HEmodiafiltration in Severe Acute Diquat (AHEAD) Poisoning
Conditions: Diquat Poisoning·Matched via name phrase
- NCT07201311·RECRUITING·Combined Gastrointestinal Decontamination in Acute Severe Poisoning
Conditions: Severe Poisoning With Cardiotropic or Psychotropic Drug · Admission to Intensive Care·Matched via name phrase
- NCT07459166·RECRUITING·A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
Conditions: Fentanyl Overdose · Fentanyl Poisoning·Matched via name phrase
- NCT04499885·RECRUITING·Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning
Conditions: Toxicity, Drug·Matched via name phrase
- NCT06574048·NOT YET RECRUITING·Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy
Conditions: Carbon Monoxide Poisoning · Carbon Monoxide Intoxication · Carbon Monoxide Encephalopathy · Carbon Monoxide-induced Parkinsonism·Matched via name phrase
- NCT05471479·RECRUITING·Activated CHARcoal in Poisoned Patient - Pilot Trial
Conditions: Charcoal, Decontamination, Poisoning·Matched via name phrase
- NCT07632937·NOT YET RECRUITING·A Study to Assess the Efficacy of Public Health Campaigns in Reducing Lead Exposure
Conditions: Lead Poisoning · Environmental Exposure·Matched via name phrase
- NCT06966765·NOT YET RECRUITING·Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute Diquat Poisoning
Conditions: Diquat Poisoning·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cyanide poisoning"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cyanide poisoning"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"poisoning"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3308) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T16:58:13.654Z
